Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11 March 2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug delivery technology, HEPtune, says it has expanded the scope of its partnership with Danish insulin giant Novo Nordisk (NOV: N).

This latest license agreement gives Novo Nordisk exclusive rights to commercialize insulin conjugated to HEPtune and non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn's, lupus, rheumatoid and psoriatic arthritis.

The companies’ previous accord covered exclusive rights to use Caisson’s proprietary heparosan-based drug delivery technology to engineer and develop compounds within undisclosed therapeutic areas (The Pharma Letter May 1, 2012).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK